Fig. 6

Stress fiber assembly in M1-CM-treated cells is mediated by IL1B, TGFB1, and AKT signaling. A Representative confocal microscopy images of MQ-CM-treated ASCs at 72 h. Supplementation of M1-CM with TGFB1 inhibitor SB431542 or IL1B inhibitor IL1RA reduced stress fiber assembly. B, C Representative immunoblots analyzing ECM-cytoskeletal signaling (B) and intracellular activated kinases (C). D Quantification of cell migration of MQ-CM-treated ASC with at least partially rescued by impaired IL1B and TGFB1 signaling. E Representative confocal microscopy images of MQ-CM-treated ASCs including co-treatment with either PI3K/AKT inhibitor LY294002 (25 µM), ERK1/2 inhibitor U0126 (10 µM), or p38-MAPK inhibitor Losmapimod (25 µM) during incubation with M1-CM treatment. F Representative immunoblots analyzing ECM-cytoskeleton signaling. G Cell migration of MQ-CM-treated ASCs with impaired AKT, ERK1/2, or p38-MAPK signaling. All scale bars indicate 20 µm. All data are shown as mean ± SEM. Asterisks indicate p values of <0.05 (*)